Floatz logo

BIFEPRUNOX

Bipolar I Disorder

Solvay PharmaceuticalsSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Bipolar I Disorder cohort.

Asset / SponsorPhaseRating
Lurasidone
Massachusetts General Hospital
Phase 4BBB
LITHIUM, ELEMENTAL
Alzamend Neuro, Inc.
Phase 4BBB
Cipralex
Massachusetts General Hospital
Phase 4BBB
Olanzapine
Alkermes, Inc.
Phase 4BBB
Valproic Acid
Bristol-Myers Squibb
Phase 4BBB

View all 50 →

Same molecule, other indications

BIFEPRUNOX is also rated in:

schizophreniaDormant
B
Indicative ·
61 / 100
View asset →
schizoaffective disorderDormant
B
Indicative ·
60 / 100
View asset →
bipolar disorderDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →